Yury Saltykov

Dr. Yury Saltykov


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
VFValentina A Feodorova
Valentina A Feodorova
ALAnna Lyapina
Anna Lyapina
MKMariya Khizhnyakova
Mariya Khizhnyakova
SZSergey S. Zaitsev
Sergey S. Zaitsev
YSYury Saltykov
Yury Saltykov
VMVladimir Motin
Vladimir Motin
The recent progress in immunoinformatics provided the basis for an accelerated development of target-specific peptide vaccines as an alternative to the traditional vaccine concept. However, there is still limited information on whether the in silico predicted immunoreactive epitopes correspond to those obtained from the actual experiments. Here, humoral and cellular immune responses to two major Yersinia pestis protective antigens, F1 and LcrV, were studied in human donors immunized with the live plague vaccine (LPV) based on the attenuated Y. pestis strain EV line NIIEG. The F1 antigen provided modest specific cellular (mixed T helper 1 (Th1)/Th2 type) and humoral immune responses in vaccinees irrespective of the amount of annual vaccinations and duration of the post-vaccination period. The probing of the F1 overlapping peptide library with the F1-positive sera revealed the presence of seven linear B cell epitopes, which were all also predicted by in silico assay. The immunoinformatics study evaluated their antigenicity, toxicity, and allergenic properties. The epitope TSQDGNNH was mostly recognized by the sera from recently vaccinated donors rather than antibodies from those immunized decades ago, suggesting the usefulness of this peptide for differentiation between recent and long-term vaccinations. The in silico analysis predicted nine linear LcrV-specific B-cell epitopes; however, weak antibody and cellular immune responses prevented their experimental evaluation, indicating that LcrV is a poor marker of successful vaccination. No specific Th17 immune response to either F1 or LcrV was detected, and there were no detectable serum levels of F1-specific immunoglobulin A (IgA) in vaccinees. Overall, the general approach validated in the LPV model could be valuable for the rational design of vaccines against other neglected and novel emerging infections with high pandemic potency.

28 June 2019 in Microorganisms
Verified
Journal Article
Open access
PDF file
VFValentina A Feodorova
Valentina A Feodorova
SZSergey S. Zaitsev
Sergey S. Zaitsev
YSYury Saltykov
Yury Saltykov
ESEdgar S. Sultanakhmedov
Edgar S. Sultanakhmedov
ABAndrew L. Bakulev
Andrew L. Bakulev
VMVladimir Motin
Vladimir Motin
Here, we present the first case of asymptomatic genital Chlamydial infection caused by the new emerging Chlamydia trachomatis (C.t.) ST13 strain genovar E, which has a double deletion of 377 bp and 17 bp in orf1 gene of the cryptic plasmid (ddCT). This case occurred in an infertile patient (case-patient) with a detectable level of Chlamydial antibodies and a spermatozoa deficiency known as azoospermia. Additionally, the ddCT strain showed the presence of a duplication of 44 bp in the plasmid orf3 and SNP in orf4, which were known as the typical characteristics of the Swedish variant of C.t. (nvCT) genovar E. Multilocus sequence typing (MLST) determined a significant difference between ddCT and nvCT in four alleles (oppA, hfiX, gitA and enoA). Both ddCT and nvCT were assigned to different genetic lineages and could be allocated to two different non-overlapping clonal complexes. Furthermore, ddCT demonstrated a considerable difference among 4–5 alleles in comparison with other C.t. strains of genovar E of ST4, ST8, ST12, and ST94, including the founder of a single relevant cluster, wtCT E/SW3 (Swedish genetic lineage). In contrast to other genovar E strains, ddCT had identical alleles with seven out of seven loci found in ST13 strains of genovars D and G, including the founder for this clonal group, D/UW-3/CX, and six out of seven loci found in its derivatives, such as ST6, ST10, and ST95 of genovars G and H. Nevertheless, MSTree V2 showed that ddCT and nvCT could have a common early ancestor, which is a parental C.t. G/9301 strain of ST9. A significant difference between ddCT and nvCT of genovar D (nvCT-D) that was recently found in Mexico was also determined as: (i) ddCT belonged to genovar E but not to genovar D; (ii) ddCT had a 44 bp duplication within the orf3 of the plasmid typical for nvCT; (iii) ddCT possessed an additional 17 bp deletion in the orf1. In conclusion, improved case management should include the clinical physician’s awareness of the need to enhance molecular screening of asymptomatic Chlamydia patients. Such molecular diagnostics might be essential to significantly reducing the global burden of Chlamydial infection on international public health.

21 February 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
VFValentina A Feodorova
Valentina A Feodorova
YSYury Saltykov
Yury Saltykov
АКАнна Колосова
Анна Колосова
LRLiudmila V. Rubanik
Liudmila V. Rubanik
NPNikolay N. Poleshchuk
Nikolay N. Poleshchuk
VMVladimir Motin
Vladimir Motin
Chlamydia trachomatis (CT) is a major cause of sexually transmitted diseases worldwide. The multilocus sequence typing (MLST) of clinical samples from random heterosexual chlamydia patients who were either asymptomatic or reported clinical manifestations of genital chlamydiosis (n = 63) in each of the seven major regions of the Republic of Belarus in 2017–2018 revealed 12 different CT sequence types (STs). We found seven known STs, ST4, ST6, ST9, ST13, ST38, ST95 and ST110, and five novel variants, namely ST271–ST275, which have not been detected elsewhere thus far. The ST4 variant was predominant (27/63, 42.9%) and detected in six out of seven regions. The two most common STs, ST9 and ST13, were regularly seen in four out of seven regions. In contrast, the remaining STs, ST6, ST38, ST95, ST110, and novel STs271-275, surfaced randomly in different parts of the country. The emergence of novel STs was registered in two regions, namely Minsk (ST271 and ST275) and Brest (ST271, ST272, ST273, and ST274). All the STs of detected CT strains were clustered into two Groups, I and III, which are characteristic of CT urogenital strains. No STs typical for Group II, specific to the LGV strains, were revealed. Our study contributes to better understanding the genetic diversity and molecular evolution of CT, one of the most important pathogens in public health worldwide.

3 December 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
ALAnna Lyapina
Anna Lyapina
NKNatalya Valentinovna Kichemazova
Natalya Valentinovna Kichemazova
MLMaxim S. Lavrukhin
Maxim S. Lavrukhin
YSYury Saltykov
Yury Saltykov
SZSergey S. Zaitsev
Sergey S. Zaitsev
VFValentina A Feodorova
Valentina A Feodorova
Background/Objectives: Lumpy skin disease (LSD) is a notifiable disease due to a marked potency for rapid spread and a significant negative economic impact on agriculture worldwide. As such, vaccination is considered the most effective way to control the disease in endemic countries, and the serological response to homologous LSDV-based vaccines is widely investigated. However, less is known about the seroconversion and duration of the immune response that is elicited by live attenuated heterologous vaccines based on the Sheeppox virus (SPPV) used for LSD prevention. This study aimed to investigate the humoral immune response in cattle immunized with a heterologous SPPV-based vaccine in the field. Methods: Commercial ELISA, based on P32 protein, as well as immunoblotting, were used to assess the antibody response in 6-month-old, 17-month-old, and older animals before and after the first immunization and revaccination. Results: Only a secondary immune response was detected when using commercial ELISA in revaccinated animals in each of the groups (83.3% and 30%, respectively). A comparative bioinformatic analysis proved a marked polymorphism of P32, derived from LSDV/SPPV/GTPV, which potentially resulted in negative responses in the ELISA. However, immunoblotting revealed a 100% seroconversion in vaccinated animals after the first vaccination and revaccination. Notably, specific antibodies were found in the sera of 80% of 6-month-old calves before the first vaccination, which had probably been passively transferred from their mothers, who were multiply vaccinated with SPPV-based vaccines. Conclusions: Several immunodominant antigens were able to induce a humoral immune response in cattle to the SPPV-based vaccine after passive and active immunization, serving as promising markers for a humoral immune response to heterologous vaccines.